ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 16th World Congress on Gastrointestinal Cancer 2014

 

25 - 28 June 2014 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  1-PD Cetuximab every 2 weeks with first-line chemotherapy in APEC study patients with metastatic colorectal cancer grouped according to EGFR expression Lucy Kilpatrick Received Received
  2-PD KRAS/NRAS and BRAF mutations in the 20050181 study of panitumumab FOLFIRI for the 2nd-line treatment of metastatic colorectal cancer: Updated analysis Marc Peeters Received Received
  2-P Detection of c-KIT and PDGFRa mutations in GIST by Next Generation Sequencing. celine de rop Received Received
  3-PD Real-life use of cetuximab in 1st-line treatment of unresectable metastatic colorectal cancer (mCRC) and outcomes after surgical resection of metastases: Updated data from the EREBUS cohort Denis Smith Received Received
  4-PD The PRIME study: Survival outcomes in patients with KRAS/NRAS wild-type metastatic colorectal cancer and non-liver-limited disease Jean-Yves Douillard Received Received
  5-PD Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC) Marta Schirripa Received Received
  6-P MicroRNA Expression Analysis in Gastric Cancer Using Clustering Method Based on Microarray Data Sally Yepes Received Received
  6-PD Panitumumab plus FOLFOX4 or panitumumab plus FOLFIRI in subjects with wild-type KRAS (exon 2) colorectal cancer and multiple or unresectable liver-limited metastases: data from the randomized, phase II PLANET study Montse Armengol Received Received
  7-O Subgroup analyses in RAS mutant, BRAF mutant and all wt metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study Chiara Cremolini Received Received
  9-P Real-world treatment patterns among patients with advanced gastric cancer in Taiwan Christine Collins Received Received
  9-O Phase I study of the investigational anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC) MLN0264 in adult patients with advanced gastrointestinal malignancies expressing GCC Jason Faris Received Received
  10-O AXE Beam: Neo-adjuvant triplet versus doublet therapy with radiation and total mesorectal excision for locally advanced rectal cancer a randomized phase II study at the end of recruitment Gabriela Chiritescu Received Received
  11-PD Circulating tumor cells (CTCs) as prognostic biomarker in patients with advanced chemorefractory, RAS wild-type colorectal cancer (CRC) treated with cetuximab or panitumumab Valeria Musella Received Received
  12-O Are the Benefits of Aspirin in Colorectal Cancer limited to PIK3CA Mutated Tumours? Ruth Langley Received Received
  13-PD Endoscopic treatment of early esophageal carcinoma: a prospective evaluation of 47 consecutive cases with promising results in patients with T1b cancers Jana Krajciova Received Received
  13-O Dietary fatty acids intake and colorectal cancer risk: the Rotterdam Study Bledar Kraja Received Received
  14-PD Clinical advantages of laparoscopic colorectal cancer surgery for the high elderly patients over 85 years old Mr Tomizawa Received Received
  16-PD TUMOR BUDDING IN COLORECTAL CANCER WITH REGARDS TO MISMATCH REPAIR STATUS PROGNOSTIC VALUE? Mia Karlberg Received Received
  17-P LOCAL RECURRENCE RATE FOLLOWING TOTAL GASTRECTOMY BY TRANSABDOMINAL APPROACH FOR SIEWERTS TYPE II ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA Ramiz Bayramov Received Received
  18-P Evaluation of patient characteristics and 5-years survival rate in patients operated for gastric cancer in Bulgaria Kostadin Angelov Received Received
  18-PD An Indirect Treatment Comparison and Cost-effectiveness Analysis Comparing FOLFIRINOX with nab-Paclitaxel plus Gemcitabine for First-line Treatment for Patients with Metastatic Pancreatic Cancer Sarah Hollmann Received Received
  19-P Primary gastric lymphomas: About 216 cases. Ines Ben Safta Received Received
  19-PD ORGAN PRESERVATION USING CONTACT RADIOTHERAPY FOR EARLY RECTAL CANCER: OUTCOMES OF PATIENTS TREATED AT A SINGLE CENTRE IN THE UNITED KINGDOM Amandeep Dhadda Received Received
  21-PD Value of KRAS, BRAF and PIK3CA Mutations and Benefits from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis Yusuke Sasaki Received Received
  22-P Pharmacokinetics of sunitinib in patients with liver cirrhosis and hepatocellular carcinoma Michele Basso Received Received
  23-PD Validation Study of a Blood-based Gene Expression Signature for Colorectal Cancer Detection Qinghua XU Received Received
  24-P Upregulation of C4.4A in hepatocellular carcinoma Magdalena Grtz Received Received
  27-P The genetic background of pancreatic cancer: Genes that might be biomarkers or indicators of metastasis to the lung Panagiotis Apostolou Received Received
  28-P Subgroup analyses based on liver metastases and the number of metastatic sites from the MPACT phase III trial of nab-paclitaxel plus gemcitabine vs gemcitabine alone for metastatic pancreatic cancer Michele Patton Received Received
  29-P nab-Paclitaxel plus gemcitabine vs gemcitabine alone for patients with metastatic pancreatic cancer: influence of primary pancreatic tumor location on efficacy and treatment exposure in the MPACT phase III trial Michele Patton Received Received
  32-P Apoptosis and anergy of T cell induced by pancreatic stellate cells derived Galectin-1 in pancreatic cancer Dong Tang Received Received
  34-P Folate intake and selected gastrointestinal cancers morbidity in Poland in the years 1960-2010 Miroslaw Jarosz Received Received
  36-P Angiogenic markers of response to neoadjuvant therapy and long-term prognosis in locally advance rectal cancers - a critical analysis of available data Olivia Lock Received Received
  37-P Malignant lymphoma diagnosed from gastrointestinal biopsy Kazuhiko Natori Received Received
  40-P A Phase I dose-escalation and pharmacokinetic Study of S-1 plus nab-Paclitaxel in Patients with Unresectable or Recurrent Gastric Cancer Kenji Ishido Received Received
  42-P Efficacy and safety of triweekly docetaxel, oxaliplatin, fluorouracil, and Folinic acid (DOFF) in patients with advanced gastric or gastroesophageal adenocarcinoma.(Poster presentation). ABLAVI ADANI-IFE Received Received
  44-P Evaluation of docetaxel, cisplatin and capecitabine (DCX) as perioperative chemotherapy for resectable gastric and esophago-gastric cancer. Marcelo Garrido Received Received
  45-P Phase II feasibility study of adjuvant S-1 plus docetaxel repeated for 6 months as adjuvant chemotherapy for Stage III gastric cancer after curative D2 gastrectomy (OGSG 1002) Yutaka Kimura Received Received
  46-P Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for Stage III gastric cancer after curative D2 gastrectomy Shigeyuki Tamura Received Received
  47-P Perioperative chemotherapy with folfox in resectable gastro-oesophageal adenocarcinoma: an AGEO multicentric retrospective study Florence MARY Received Received
  49-P Immediate and long-term outcome of ESD for differentiated intramucosal gastric cancer compared to surgical resection Sung Min Park Received Received
  52-P Gastric Cancer in Young Adults: Experience from Nepal Bishnu Prasad Kandel Received Received
  55-P Perioperative chemotherapy of resectable gastroesophageal cancer in elderly patients: a retrospective analysis Catarina Cardoso Received Received
  56-P Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced gastroesophageal cancer: A retrospective pooled analysis of individual patient data Silvia Spoerl Received Received
  57-P Chemotherapy and target therapy of advanced stomach cancer. Olga Kuznetsova Received Received
  58-P Single centre experience of palliative chemotherapy for upper gastrointestinal cancer Victoria Plested Received Received
  59-P A single centre review of incidence of venous thromboembolism (VTE) in patients receiving palliative chemotherapy for upper gastrointestinal cancers and the impact on outcomes Victoria Plested Received Received
  60-P Comparative study between using antracycline based and taxane based regimens as first line therapy for advanced and metastatic gastric cancer. Abeer Ibrahim Received Received
  66-P Does biology and location predict chemotherapy benefit? Patients with distal gastric cancer have superior outcome with addition of taxanes into combination chemotherapy while proximal and diffuse gastric cancers dont. ali murat sedef Received Received
  67-P Treatment Patterns and Outcomes of Patients with Gastric Cancer in the US: A retrospective analysis of electronic medical record (EMR) data Lisa Hess Received Received
  69-P Costs and patterns of gastric cancer care in the US: A retrospective analysis of administrative claims data Lisa Hess Received Received
  71-P Gastric cancer risk screening with combined assay for serum anti-Helicobacter pylori IgG antibody and pepsinogen level, so-called ABC method ; Can we need imaging study for gastric cancer screening ? Takayuki Nakamura Received Received
  73-P COMPARISON OF THE AVERAGE BODY WEIGHT AND WAIST CIRCUMFERENCE IN PATIENT WITH BARRETTS OESOPHAGUS AND PATIENT WITHOUT LESIONS Miros&322;aw Jarosz Received Received
  79-P The risk factors of postoperative external drainage after gastrectomy without prophylactic intra-peritoneal drainage for gastric cancer Janghee Lee Received Received
  80-P Treatment outcome after D2 dissection in operable gastric cancer a retrospective analysis. Shaikat Gupta Received Received
  82-P Results After D-2 Resection With Spleen And Distal Pancreas Preserved For Gastric Cancer Treatment Antonio Chiappa Received Received
  83-P Devine gastric exclusion: for a better palliation in pyloric obstruction Sara Carvalhal Received Received
  84-P Impact On Survival Of The Number Of Lymph Nodes Removed In Extended D-2 Lymphadenectomy For Gastric Cancer Antonio Chiappa Received Received
  85-P Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with advanced gastric cancer Satoru Iwasa Received Received
  89-P Transient elastography (FibroScan) predictor of hepatocellular carcinoma prognosis in patients referred to surgical treatment Andra Iulia Suceveanu Received Received
  91-P Incidental Hepatocellular Carcinoma: A hidden foe for liver transplant recipients? Renata Senkerikova Received Received
  92-P SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN NORTHERN GREECE. THE ROLE OF HBV INFECTION AND THE VALUE OF SORAFENIB IN INTERMEDIATE STAGE OF DISEASE. Georgios Nalmpantidis Received Received
  93-P Treatment Outcomes of Patients with Extremely Advanced Inoperable Hepatocellular Carcinoma (HCC) after Yttrium-90 Radioembolization Victor Lee Received Received
  95-P Efficacy of continued sorafenib treatment after radiological confirmation of disease progression in patients with advanced hepatocellular carcinoma Yoshiyuki Wada Received Received
  98-P Health Related Quality of Life and Survival in Patients Diagnosed with Hepatocellular Carcinoma and Treated with Transarterial Chemoembolization or Yttrium-90 Kathryn Bress Received Received
  100-P A retrospective study of liver stereotactic ablative radiotherapy: 21 months of follow-up Samuel Palumbo Received Received
  101-P The role of Choi criteria in assessing response to tyrosine kinase inhibitors (TKIs) in patients with advanced hepatocellular carcinoma (HCC) Fiona McCarthy Received Received
  103-P Comparison of Hepatic Resection and Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Meta-Analysis of 16,103 Patients Qinghua Xu Received Received
  105-P Oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in first-line treatment of Asian patients with MET-positive advanced hepatocellular carcinoma and Child-Pugh class A liver function: Phase Ib/II, multicenter, randomized trial Ann-Lii Cheng Received Received
  106-P The impact of FOLFIRINOX chemotherapy on the treatment pattern of patients with pancreas cancer seen at a tertiary referral centre in the UK. Neha Chopra Received Received
  109-P Performance status remained the most important prognostic factor in pancreas cancer patients, single center experience &304;brahim Trker Received Received
  112-P Evaluation of bowel doses in patients undergoing dose escalated post operative Intensity Modulated Radiotherapy in Perimapullary Cancers AMIT BAHL Received Received
  116-P Standard clinical practice of FOLFIRINOX in Advanced/Metastatic Pancreatic Cancer (PC) Patients: A Canadian Registry jean maroun Received Received
  117-P Gemcitabine(G)-Erlotinib(E) versus Gemcitabine-Erlotinib-Capecitabine(C) in the first line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from Spanish TTD Collaborative Group Susana Rodríguez Received Received
  118-P FOLFIRINOX IN PANCREATIC CANCER: THE NATIONAL CANCER INSTITUTE OF MILAN SINGLE EXPERIENCE. KATIA FIORELLA DOTTI Received Received
  124-P LYMPH NODE INVOLVEMENT IN STANDARD LYMPHADENECTOMY FOR RESECTABLE PANCREATIC HEAD ADENOCARCINOMA Daniel Kostov Received Received
  125-P A retrospective study of the prognostic value of various pathological and immunohistochemical features in tissue samples from patients with pancreatic neuroendocrine neoplasms Nizar BAWAHAB Received Received
  127-P Multimodality treatment approach for locally advanced pancreatic cancer Alexander Siebenhuener Received Received
  128-P Prognostic significance of CEA, CA19-9 and CA72-4 serum level before and after preoperative chemotherapy of esophagogastric junction adenocarcinoma Milada Zemanova Received Received
  130-P Serum albumin (SA) as a predictor of response to chemotherapy in patients with locally advanced (LA) esophageal cancer. Erika Ruiz-Garcia Received Received
  132-P Is a complete remission of intestinal metaplasia a suitable endpoint in patients undergoing radiofrequency ablation (RFA)? Long-term results of RFA treatment in 67 consecutive patients Jana Krajciova Received Received
  135-P Phase I trial of 5-FU, Docetaxel and Nedaplatin combination therapy for metastatic esophageal cancer Shinichi Nishina Received Received
  137-P LOCAL ADVANCED ESOPHAGEAL CANCER: PRECISE PREDICTION OF 5-YEAR SURVIVAL AFTER COMBINED ESOPHAGOGASTRECTOMIES Oleg Kshivets Received Received
  141-P Electroneurography in evaluation of peripheral neuropathy during oxaliplatin-based chemotherapy for colorectal cancer. Aneta Zygulska Received Received
  146-P To select the therapies in gastric carcinoid tumors Sei Kurokawa Received Received
  148-P Presentation of Insulinoma in developing world Manish Kaushal Received Received
  149-P Anorectal malignant melanoma experience of a single portuguese institution Isália Miguel Received Received
  151-P Gastric neuroendocrine tumors: a single center experience. IOANNIS PILPILIDIS Received Received
  158-P Image-guided hypofractionated stereotactic ablative radiotherapy for the liver: the MAASTRO experience Lien Van De Voorde Received Received
  159-P Diagnosis, staging and treatment of cholangiocarnioma; a retrospective analysis of our last decade of experience Heppell Hebert Mathieu Received Received
  160-P GASTROINTESTINAL CANCERS: EPIDEMIOLOGICAL, CLINICAL, HISTOLOGICAL AND THERAPEUTIC CHARACTERISTIC (210 CASES TREATED IN THE RADIOTHERAPY DEPARTMENT OF UNIVERSITY HOSPITAL OF HASSAN II-FES-MOROCCO BETWEEN JANUARY 2012 AND DECEMBER 2013) fatima zahra farhane Received Received
  161-P The provision of a pre-operative immunomodulating diet in patients undergoing radical resection for upper gastrointestinal cancers does not reduce the risk of post-operative chest infection Petra Goldsmith Received Received
  167-P INTERNATIONAL SCIENTIFIC COMMUNICATIONS IN THE FIELD OF RECTAL CANCER PATIENTS QUALITY OF LIFE Daniel Kostov Received Received
  168-P INTERNATIONAL VISIBILITY OF RESEARCH ON INTERSPHINCTERIC RESECTIONS FOR RECTAL CANCER Daniel Kostov Received Received
  169-P Neoadjuvant chemoradiation for rectal cancers Charu Singh Received Received
  170-P EPIDEMIOLOGY OF RECTAL CANCER IN THE REGIONS OF VARNA AND DOBRICH, BULGARIA Daniel Kostov Received Received
  171-P Incidence of Kirsten-Ras Gene Mutation and Its Association with Clinical and Pathological Factors in Colorectal Carcinoma: single institute retrospective experience Vinayak Maka Received Received
  174-P Association between colorectal cancer survival outcomes and GWAS-identified colorectal cancer susceptibility polymorphism in Korean population Byung Woog Kang Received Received
  175-P Simultaneous detection of KRAS, NRAS and BRAF hotspot mutations on Ion Torrent PGM platform. celine de rop Received Received
  176-P The levels of methionine determined by amino acid profiling correlate with the degree of methylation in colon cancer tissues. Yuji Takayama Received Received
  177-P KRAS Mutation Status in Colombian patients with colorectal cancer: Analysis of 844 consecutive cases Rocío del Pilar López Panqueva Received Received
  179-P Intronic SMAD7 gene polymorphisms, rs12953717 and rs4464148, in association with risk of Colorectal Cancer Shaghayegh Derakhshani Received Received
  180-P BEVACIZUMAB IN COMBINATION WITH IRINOTECAN AND CAPECITABINE AS FIRST-LINE TREATMENT FOR mCRC EFFICACY AND SAFETY SAA JUNGI&262; Received Received
  181-P Detention of molecular changes between primary tumor (PT) and synchronous resected liver metastases (srLm) in colo-rectal cancer (CRC) patients after first line cetuximab based chemotherapy (CT). DANIELA ADUA Received Received
  184-P Selective, synergic and additive interaction types between 5-fluorouracil and 2-oxohexyl isothiocyanate after sequential treatment in colon cancer cell lines Ma&322;gorzata Milczarek Received Received
  185-P Combined administration of 5-fluorouracil as well as 2-oxohexyl isothiocyanate with selol give synergistic toxic effect on HT -29 colorectal cancer cell lines. Lidia Sliwka Received Received
  187-P Incidence of Hepatic Resection among Colorectal Cancer Patients with Liver Metastases Keith Betts Received Received
  188-P Isothiocyanates are chemopreventive compounds and reduce the MDR phenomenon - study on normal and colon cancer cells Katarzyna Lubelska Received Received
  191-P Is there a trend toward lower participation in colorectal cancer screening among certain populations? Olivier Galut Received Received
  192-P ABDOMINAL OBESITY IS ASSOCIATED WITH THE NUMBER OF COLORECTAL POLYPS IN MEN BUT NOT IN WOMEN Miros&322;aw Jarosz Received Received
  194-P KRAS genotype and the prevalent c.35 G A mutation affect significantly worse prognosis of metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab. Gemma Bruera Received Received
  195-P Clinical validation of a novel multiplex kit for all RAS mutations in colorectal cancer: Results of RASKET (RAS KEy Testing) prospective multicenter study Toshihiro Kudo Received Received
  196-P Expression of aquaporin-1, aquaporin-3, and aquaporin-5 with nodal metastasis in colon cancer Byung Woog Kang Received Received
  197-P Comparison of a new multiplexed multigene approach with pyrosequencing in diagnostic molecular biology of colorectal cancer (CRC) Giovanna De Maglio Received Received
  198-P KRAS mutations in colorectal cancer patients in Serbia: 5 years experience of central testing Radmila Jankovic Received Received
  199-P Analysis of Molecular Alterations for Predicting Clinical Benefit to Cetuximab plus Chemotherapy in first-line Metastatic Colorectal Cancer (mCRC) Javier Sastre Received Received
  202-P Cyclooxygenase-2 (COX-2) expression in a cohort of Greek patients with colorectal cancer (CRC) DIMITRIOS TZILVES Received Received
  203-P Value of monitoring CEA in patients with colon cancer receiving adjuvant chemotherapy Andrea Nagy Received Received
  205-P Cytokines, depression and anxiety in colorectal cancer patients in different stages of the antitumor therapy Dr. Miranda Received Received
  206-P Hyperuricemia at time of diagnosis is a poor prognostic factor for patients with colorectal cancer: a pilot study Ozgur Tanriverdi Received Received
  209-P Tolerability and Safety of cytotoxic chemotherapy in patients over 80 with colorectal cancer (CRC) at Heart of England NHS Foundation Trust (HEFT) Racha Kussaibati Received Received
  210-P Under prescription of targeted therapy in first-line metastatic colorectal cancer in elderly people: a cohort study in a French center. Amaury daste Received Received
  211-P Prespecified subgroup analyses in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer HIROSHI TAMAGAWA Received Received
  213-P COLORECTAL CANCER IN PATIENTS AGE 40 AND UNDER: A RETROSPECTIVE ANALYSIS OF DATABASE FROM THE INSTITUTE OF ONCOLOGY AND RADIOLOGY OF SERBIA Jelena Spasic Received Received
  214-P Use of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer (mCRC): a post-hoc analysis of the GLUTOX study Francois Leblond Received Received
  215-P Efficacy, safety and patient-reported outcomes of oxaliplatin-based chemotherapy in elderly patients with colorectal cancer (CRC): a post-hoc analysis of the GLUTOX study Francois Leblond Received Received
  216-P Evaluating the learning curve of Magnetic Resonance Imaging (MRI) as a predictive tool in locally advanced rectal cancer (RC) - a retrospective 12-year experience. CHA LEN LEE Received Received
  220-P The sequential administration of XELOX and XELIRI was effective, feasible and manageable for patients with mCRC. Taro Fukui Received Received
  223-P Survival advantage of metformin in patients with colorectal cancer and type II diabetes mellitus: The Middle Eastern perspective. Ali Shamseddine Received Received
  230-P Salvage chemotherapy in metastatic colorectal cancer with combination of capecitabine and mitomycin C. Aneta Zygulska Received Received
  231-P Efficacy and safety of bevacizumabhepatic arterial infusion chemotherapy of FOLFIRI for unresectable colorectal liver metastases Yoshiyuki Wada Received Received
  232-P Extending targeted therapy beyond first-line (1L) chemotherapy backbone: real-world treatment patterns and outcomes in patients with metastatic colorectal cancer (mCRC) Manasee Shah Received Received
  233-P Assessment of morphological response contributes to selection of candidates for rescue liver resection among patients undergoing chemotherapy for initially unresectable colorectal liver metastasis Koichi Suzuki Received Received
  234-P Analysis of Glasgow Prognostic Score(GPS) in KRAS Exon2 wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901 SATOSHI YUKI Received Received
  236-P The PRIME study: Survival outcomes for patients with RAS/BRAF wild-type metastatic colorectal cancer, by baseline ECOG performance status Marc Peeters Received Received
  237-P Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in the UK Karin Sennfalt Received Received
  238-P Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in Italy Karin Sennfalt Received Received
  244-P Single institution results of first- line treatment with bevacizumab plus chemotherapy in metastatic colorectal cancer (mCRC) Jaroslava Barkmanova Received Received
  246-P Management of patients with colorectal liver metastasis harboring more than 5 multiple tumors Kosuke Ichida Received Received
  248-P Cetuximab with irinotecan or oxaliplatin for 1st-line metastatic colorectal cancer: updated data of effectiveness in the EREBUS cohort compared to pivotal trials Denis Smith Received Received
  249-P Conversion chemotherapy for technically unresectable colorectal liver metastases: a retrospective, single-center study comparing chemotherapy alone or in combination with cetuximab or bevacizumab. Vincenzo Dadduzio Received Received
  250-P Bevacizumab in combination with neoadjuvant therapy in elderly patients with liver metastases of colorectal cancer-Single center experience marija ristic Received Received
  251-P Bevacizumab in the first line therapy of metastatic colorectal cancer in older patients, study AVEX in clinical practice. Lenka Ost&345;íková Received Received
  252-P Cost-effectiveness of different chemotherapy strategies for patients with advanced colorectal cancer in Brazil: a Public Health System perspective Andre Sasse Received Received
  259-P Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in North Japan multicenter phase II study (NORTH/HGCSG1003) Norihiko Takahashi Received Received
  261-P The management of peritoneal surface malignancies at the American University of Beirut Medical Center: initial experience Faek Jamali Received Received
  266-P Adjuvant regorafenib in stage IV colorectal cancer (CRC) after curative treatment of liver metastases: A phase III randomized, placebo-controlled study (COAST) Eric Van Cutsem Received Received
  267-P Dose-dense temozolomide (TMZ) in patients with advanced chemorefractory colorectal cancer (CRC) and MGMT promoter methylation Filippo Pietrantonio Received Received
  269-P The CAIRO4 study: The role of surgery of the primary tumor with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer: a randomized phase III study. Jorine t Lam - Boer Received Received
  272-P Neoadjuvant Chemotherapy capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer Takeshi Kato Received Received
  275-P Clinical significance of tumour regression grade in locally-advanced rectal cancer treated with preoperative chemoradiotherapy ALBA HERNANDEZ Received Received
  279-P Ordinary rectal adenocarcinoma vs. primary rectal signet-ring cell carcinoma LOUKILI KAOUTAR Received Received
  10008-O Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone, as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer: the POSEIDON Phase I/randomized Phase II trial Elena Elez Received Received
  10243-P Deep responders represent a group with excellent survival in patients with metastatic colorectal cancer(mCRC) treated with Triplet chemotherapy regimens(TCR) Shouki Bazarbashi Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
09:24
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 16th World Congress on Gastrointestinal Cancer 2014

 

25 - 28 June 2014 Barcelona
HELP LINE
Manage Orders
FAQs

EXTENSION OF DEADLINE FOR EPOSTER SUBMISSION
Due to many requests, we are allowing submission of ePosters only (not for the printing service) until 20th June at 23:59 GMT+1. 

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 29/06/2014 TO 25/06/2016
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.16wcgc.2014 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 20/06/2014
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster







PosterSessionOnline
Logo Draft
 
Logo Cert